Avonex (recombinant IFN-β-1a) / Biogen 
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avonex (recombinant IFN-β-1a) / Biogen
CONNECT, NCT02283853 / 2013-002318-11: Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Active, not recruiting
3
156
Europe, Canada, US, RoW
dimethyl fumarate, BG00012, Tecfidera, Interferon β-1a, Avonex
Biogen
Relapsing-Remitting Multiple Sclerosis
09/25
09/25
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
07/24
05/27
NCT00676715 / 2007-006338-32: A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Checkmark
Mar 2013 - Mar 2013: 
Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Checkmark Data AAN (MS)
More
Completed
2
220
Europe, Canada, US, RoW
Placebo, Ocrelizumab, RO4964913, Avonex, Interferon-beta-alpha1
Genentech, Inc., Roche Pharma AG
Multiple Sclerosis, Relapsing-Remitting
03/12
11/23
2016-002180-33: Multiple sclerosis therapy with transdermal myelin peptide stimulation.

Ongoing
2
220
Europe
SMderpept, Avonex, Powder for cutaneous solution, Solution for injection
Centrum Neurologii Krzysztof Selmaj, The National Centre for Research and Development
relapsing-remitting multiple sclerosis, multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn
2
300
NA
Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa
Biogen
Relapsing Multiple Sclerosis
09/24
09/24
NCT05936229: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Not yet recruiting
1/2
24
US
Interferon Beta-1A, 145258-61-3, Avonex, BG9418, Rebif, Recombinant interferon beta-1a, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized axial tomography (procedure), Positron Emission Tomography, Pet Scan, Positron emission tomography (procedure), Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Lumbar Puncture, LP, spinal tap, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biological Sample Collection, Biopsy, BIOPSY_TYPE, Bx
Fred Hutchinson Cancer Center, Faron Pharmaceuticals Ltd
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
10/27
10/27
INFORM, NCT06053749: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

Not yet recruiting
N/A
100
Europe
Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs)
Bayer, Biogen Netherlands B.V, Novartis Europharm Limited, Merck Europe B.V.
Multiple Sclerosis (MS)
03/26
03/26
NCT05658497: Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Recruiting
N/A
908
Europe, US
Diroximel Fumarate, VUMERITY, BIIB098, Avonex, BG9418, interferon beta-1a, Tysabri, Natalizumab, BG00002, Dimethyl Fumarate, Tecfidera, DMF, BG00012
Biogen
Multiple Sclerosis
07/32
07/32

Download Options